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Abstract
Background: Virus-induced dendritic cells (DCs) functional deficiency leads to sub-optimal initiation of adaptive
immune responses and consequently chronic infection establishment. The present study reports an advanced
hepatitis C virus (HCV) therapeutic vaccine model based on In vivo enrichment of DCs with barberry ethanolic
crude extract (BCE) then pulsing them with HCV core protein.
Methods: DCs were enriched by BCE intravenous injection in BALB/c mice. Vaccine efficiency was assessed by flow
cytometric analysis of splenocytes of immunized mice, cytokine profiling, cytotoxic T lymphocyte assay, and
humoral immune response assessment.
Results: There was no significant difference in surface phenotypic characterization of splenocytes from mice
immunized with non-BCE-enriched-core-pulsed DCs (iDcs-core) compared to those from mice injected with
RPMI-1640 medium. However, splenocytes from mice immunized with BCE-enriched-core-pulsed DCs showed
197 % increase in CD16+ population, 33 % increase in MHCII+ population, and 43 % decrease in CD3+ population.
In iDCs-core group, 57.9 % greater anti-core cytotoxic T lymphocyte activity, up-regulation in interferon gamma
and interleukin (IL) -12 expression, and down-regulation in IL-4 and IL-10 were recorded. Moreover, sustained
specific anti-core antibodies were detected only in sera of the same group.
Conclusions: results indicate that BCE-enriched-core-transduced DCs may serve as a new model for
immunotherapy of HCV chronic infection.
Keywords: IL 12, Berberis vulgaris, Th-1, IL 4, INF-γ
Abbreviations: BCE, Barberry ethanolic crude extract; BSA, Bovine serum albumin; CD, Cluster of differentiation;
CTL, Cytotoxic T lymphocytes; DC, Dendritic cells; ELISA, Enzyme linked immunosorbent assay; Flt3, Fms-like
tyrosine kinase receptor-3; GM-CSF, Granulocyte-macrophage colony-stimulating factor; HCV, Hepatitis C virus;
iDCs group, That received BCE-induced DCs; iDCs-core group, That received BCE-induced DCs transduced with
core protein; IFN-α, Interferon α; IL 12, Interleukin 12; LDH, Lactate dehydrogenase; LTβR, Lymphotoxin β receptor;
MHCII, Major histocompatibility complex class II; MTT assay, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide assay; nDCs group, That received non-BCE-induced DC; nDCs-core group, That received non-BCE-
induced DCs transduced with core protein; NFkB, Nuclear factor kappa B; NK cells, Natural killer cells; NO, Nitric
oxide; PBS, Phosphate buffered saline; PRPMI - 1640 group, That received complete medium; SVR, Sustained
virologic response; TCR, T cell complex receptor; Th1, T helper 1; Th2, T helper 2; TNFR, Tumor necrosis factor
receptor
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Background
Approximately 180 million people worldwide are chron-
ically infected with HCV, but most are unaware of the
infection based on the lack of symptoms at its first
stages [1]. The global seroprevalence of anti-HCV anti-
bodies is estimated to be 2.8 %. Central and East Asia
and North Africa/Middle East are estimated to have the
high viral prevalence >3.5 %; [2] the highest estimated
annual number of HCV infections locates in Egypt
where there is more than 150,000 new patients every
year [3].
Standard of care (SOC) antiviral therapy for HCV
today consists of pegylated IFN-α-2a or -2b in combin-
ation with ribavirin. Patients with genotype 1 and 4 typ-
ically require 48 weeks of SOC treatment with sustained
virologic response (SVR) of around 40 % to 50 %, while
those with genotype 2 and 3 require 24 weeks of treat-
ment with SVR of around 70 % to 80 % [4].
Development of an effective vaccine against HCV in-
fection has long been defined as a difficult challenge.
This is due to the quasispecies nature of the virus due to
the lack of proofreading activity of the viral RNA-
dependent RNA polymerase, and the observation that
convalescent humans and chimpanzees could be re-
infected upon re-exposure [5]. HCV chronic infection is
characterized by the absence of efficient antiviral T cell
responses. Virus-induced defect in DCs function is one
of the mechanisms responsible for immune evasion of
HCV. [6] A number of studies described a significant
down-regulation of DCs function in HCV infected pa-
tients, where Th1/Th2 balance was shifted towards Th2
up-regulation [7, 8]. Thus, vaccination strategies to
induce strong anti-HCV T cell responses are essential
for both of prophylactic and therapeutic purposes.
DCs are of the greatest antigen presenting capacity
among all immune effectors; therefore enriching such
cells with a natural and potent agent to counteract the
defect caused by viral infection is of a major concern.
Immunization with DCs loaded with some conserved
viral parts offers a new approach for induction of a
specific antiviral immunity and developing a novel
therapeutic strategy in HCV infection therapeutics [9].
Berberis vulgaris L. is well known medicinal plant with
traditional herbal medical history. Used in many civiliza-
tions as a curative herbal remedy in the homeopathic
system of medicine [10]. The most important constituents
are isoquinoline alkaloids, such as berberine, berbamine
and palmatine [11].
It was demonstrated that treatment of macrophages
and DCs with berberine; a benzodioxoloquinolizine
alkaloid present in Berberis vulgaris plant, significantly
induced interleukin (IL) -12 production in a dose-
dependent manner, Therefore, it could be counteracting
the effect of HCV infection of misbalancing the Th1/
Th2 cytokines ratios to evade the immune response of
the host [12].
Our published in vitro study showed that the treat-
ment of mice splenocytes with BCE induced inter-
feron gamma (IFN-γ) production and increased the
level of CD11c which indicated the positive incre-
ment of antigen representing cells specially DCs.
Moreover, BCE increased the production of both
IFN-g and IL-12 and decreased the production of IL
10 and IL 4 therefore BCE shifted the maturation to-
wards the Th1 [13].
Therefore, therapeutic DCs vaccine may hold its
promises by working on DCs maturation and prolifera-
tion, since DCs of chronically infected patients are under
negative regulation of the virus itself. Immunization
strategies in chronic HCV infection may have one cen-
tral aim in the future: targeting directly or indirectly
DCs to induce vigorous immune responses that are able
to eliminate the virus. The present study reports an
advanced hepatitis C virus (HCV) therapeutic vaccine
model based on In-vivo enrichment of DCs with barberry
ethanolic crude extract (BCE) and pulsing them with
HCV core protein.
Methods
BEC extraction and animal modeling
Barberry dried roots were purchased and imported from
Iran. They were authenticated by Prof. Dr Salama El-
Dareir from the Botany Department, Faculty of Science,
Alexandria University, Egypt. First, this classification was
determined based on the data about the plant, published
in Dragon Herbarium (https://dragonherbarium.com/prod-
ucts/barberry-root-bark-c-s-wc-berberis-vulgaris).
BEC was prepared from Berberis vulgaris root accord-
ing to Abd-Elwahab et al., [14] and Ghareeb et al. [15]
where The dried powdery roots of barberry was exhaust-
ively defatted with petroleum ether and subjected to
steam distillation method for ethanolic gradient extrac-
tion with Soxhlet apparatus. The ethanolic extract was
concentrated to minimum volume using rotary evapor-
ator then lyophilized to obtain a powder extract of bar-
berry (25 %). The barberry extract powder form was
kept at −20 °C until subjected to further biochemical
analysis BALB/c female mice, inbred strain (8–10 weeks
of age, 25–30 g body weight) were purchased from
experimental animal house (Tudor Belharis Research In-
stitute), and housed in the animal house of Medical
Technology Centre, Medical Research Institute, Alexan-
dria University, Egypt. all study protocols for animal and
biological tissue samples treatment, involved in this
study, were firmly subjected to ethical instructions
outlined by Animal Ethics Committees (AEC) that pub-
lished via The National Health and Medical Research
Council (NHMRC) policies and guidelines that
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recommended by the Egyptian Ministry of Health and
Population, High Committee Of Medical Specialties,
Arab Republic of Egypt [16]. This study granted permis-
sion from the Biomedical technology, SRAT-city and
Biochemistry Department, Faculty of Science, Alexandria
University, following approval of the Research Ethics
Committee, Faculty of Pharmacy, Alexandria University.
Animals were grouped and housed in metal cages
(eight mice/cage), maintained at approximately 23–25 °C
with a 12 h light/dark cycle and received laboratory
basal diet and tap water for 1 week acclimation period
throughout the study period. In this study, two suc-
cessive animal models for DCs enrichment and
immunization were used.
In vivo DCs enrichment, separation and transduction
DCs were enriched by intravenous injection of mice with
60 mg/kg of BEC eight times every other day. Mice were
grouped into two groups (8 mice/group); the first was
designated as BCE-induced-DCs, while the second
which received no treatment was designated as non-
BCE-induced-DCs. Two days after the last injection
mice were euthanized by cervical dislocation and spleens
were dissected and dissociated with cell dissociate (gen-
tleMACS™, Miltenyi Biotec, Germany) for single-cell sus-
pension in RPMI-1640 plain medium (Lonza, USA).
Cells were centrifuged at 1650 rpm for 5 min, brake 9/9,
at 25 °C. Pellets were dispersed with 10 ml of red blood
cells lysis buffer, and centrifuged at the same conditions.
Pellets were collected and dispersed again in 1 ml RPMI
- 1640 complete medium and cells were counted using
0.4 % trypan blue. DCs were separated from total sple-
nocytes using anti-CD11c microbeads (MACS, Miltenyi
Biotec, Germany). Influence of BEC on enriching DCs
population was evaluated by staining the separated cells
with PE-conjugated hamster anti-mouse CD11c antibody
(Miltenyi Biotec, Germany) and counting CD11c+ cells
using FACS analysis (Becton Dickinson, USA (using
CellQuest Pro Software. CD11c+ cells were transduced
with HCV core recombinant peptides (Sigma Aldrich,
USA) at a concentration of 2 μg/106 cells.
Phenotypic analysis of DCs
After the DCs were collected, the level of CD11c and
MHCII were detected by FACSCalibur flow cytometer
(BD Biosciences). Moreover, cytokines expression (IL4,
IL10, IL 12 and INF-gamma) was performed by RT-PCR
beside IL 12 and INF-gamma proteins levels were mea-
sured by ELISA (Komabiotech, Korea).
Invivo immunization
This step required an animal model design of six groups
of BALB/c mice (eight mice/group). According to the
general aspects of vaccination of world health
organization (WHO), primary immunization schedules
includes at least two vaccine doses, optimally repeated at
a minimal interval of 3–4 weeks to generate successive
waves of immune response. Accordingly, mice were
treated subcutaneously three times at four-weeks inter-
vals with different DCs subsets obtained from animal
model A (ex-vivo transduced with core recombinant
protein or non-transduced) resulting in the following
groups: 1) Negative control group that received no treat-
ment, 2) RPMI - 1640 group that received complete
medium, 3) nDCs group that received 0.1 × 106 non-
BCE-induced DCs at the first injection, and 0.05 × 106
of the same cells at the second and third injections. 4)
nDCs-core that received 0.1 × 106 non-BCE-induced
DCs transduced with core protein at the first injection,
and 0.05 × 106 at the second and third injections. 5)
iDCs group that received 0.1 × 106 BCE-induced DCs at
the first injection, and 0.05 × 106 at the second and third
injections. 6) iDCs-core group that received 0.1 × 106
BCE-induced DCs transduced with core protein at the
first injection, and 0.05 × 106 at the second and third
injections. Immunization scheme was performed accord-
ing to sakai et al. [17] with modifications as follows: 1) A
dose lower than 0.1 × 106 DCs/mouse had been admin-
istrated to mice to avoid death with hypoxia, 2)
Immunization was performed in four weeks intervals,
not three weeks intervals.. After immunization period,
mice were euthanized by cervical dislocation at day 7
after the last booster exposure, and spleens were dis-
sected and dissociated as previously mentioned.
Phenotypic characterization of splenocytes of immunized
mice by flow cytometric analysis
Splenocytes were washed and harvested in a 96-well
plate. 10 μl of FITC-conjugated monoclonal anti-mouse
MHCII (Miltenyi Biotec, Germany), APC-conjugated
monoclonal anti-mouse Fcγ RIII/CD16, and PE-
conjugated monoclonal anti-mouse CD3 (R&D systems,
UK) antibodies were added individually to wells contain-
ing 0.1 × 106 cells dispensed in 25 μl PBS, and incubated
at 4 °C for 45 min according to the manufacturer’s
instructions. After incubation, the unreacted antibody
reagent was discarded by washing the cells twice with
4 ml of same 0.5 % BSA in PBS. Cells were re-suspended
in 200 μl PBS/BSA buffer for flow cytometric analysis.
Cytokines profile
Cytokines profile was studied on the genomic level by
reverse transcriptase polymerase chain reaction (RT-
PCR), and on protein level by enzyme linked immuno-
sorbent assay (ELISA). Total RNA was extracted from
immunized splenocytes (106 cells) according to the
method of Chomczynski et al. [18] First strand cDNA
was synthesized using RevertAid™ first strand cDNA
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synthesis kit (Fermentas, Thermo fisher scientific,
Germany). RT was performed using DreamTaq™ Green
PCR master mix (2X) (Fermentas, Thermo fisher scien-
tific, Germany), and cytokine-specific oligonucleotide







CATAGCAGT- 3′; IL-4, 5′-TTGTCTCTCGTCACT
GACGCA-3′, 5′-TACGAAGCACCTTGGAAGCC-3′.
The amplification was performed at initial step at
95 ° C for 15 min, followed by 40 cycles of a de-
naturation step at 90 °C for 30 s, an annealing step at
primer’s melting point - 5 °C for 1 min, an extension
step at 72 °C for 8 min, and a final extension step at
72 °C for 10 min. The resulting PCR fragments were
visualized on 1.5 % agarose gels, and gel bands were
revealed using gel documentation system. The relative
expression quantity was evaluated by the ratios of
band intensity to GAPDH using AlphaView software.
Cytoplasmic contents of cytokines protein expression
of INF-γ was screened according to the instructions
of Mouse INF-γ ELISA kit (Komabiotech, Korea).
Determination of the optimum effector cells: target cells
ratio (E:T)
In a 96-well rounded-bottomed plate, splenocytes of
non-treated mice were co-cultured with murine EL4 cells
(ATCC® TIB39 ™) with a final cell count of 0.5 × 106 cell/
well at E: T ratios of 1:25, 1:12.5, 1:6.2, 1:3.1 and 1:1.6. The
plate was incubated at 37 °C for 4 h in presence of 5 %
CO2. 20 μl aliquots of MTT (Sigma-Aldrich, USA) (were
added in the dark to each well, and the plate was re-
incubated at 37 °C and 5 % CO2 for 4 h. The plate was
centrifuged at 25 °C, 2000 rpm and brake 9/9 for 10 min.
Supernatants were discarded, 200 μl of DMSO was added
to each well, and the plate was agitated using a shaker
(ThermoFisher) for 5 min. Absorbance was determined at
570 nm on microtiter plate reader (BioTek, USA).
EL4 cells transduction with core protein
Transduction of 1 × 106 cell of EL4 with 10 μg of core
recombinant peptides was performed using protein de-
livery system BioPORTER quickEase protein delivery Kit
(Sigma-Aldrich, USA). Transduction was evaluated using
anti-HCV core antigen antibody (Abcam, UK) as de-
scribed by Coligan et al. [5].
Cytotoxic T lymphocyte assay by LDH and MTT
Cells (1.0 × 106) were dispensed at an E: T ratio of 1:1.6
into a 96-well rounded plate, brought to 150 μl with
complete medium and incubated at 37 °C for 4 h in
presence of 5 % CO2. Co-cultured cells were centrifuged
at 25 °C, 2000 rpm and brake 9/9 for 10 min. LDH
release was assessed according to the instructions of
Lactate cytotoxicity assay kit (Cayman chemicals, USA).
With the same plate set-up, MTT assay was performed
as previously described.
Monitoring humoral response
Anti-HCV core IgG antibody levels) total IgG) in the
serum of each immunized mouse were screened against
core recombinant peptides and non-structural protein3
(NS3) antigen (Sigma-Aldrich, USA) according to Lazdina
et al. [19] Efficiency of anti-core antibodies was estimated
using non-structural protein 3 (NS3) as a negative control.
Statistical analysis
Data were analyzed by one-way analysis of variance
(ANOVA) using Primer of Biostatistics (version 5) soft-
ware program. Significant differences (p < 0.05) between
the means ± SD were determined using multiple com-
parisons Student-Newman-keuls test.
Results
Remarkable increase in splenic CD16 and MHCII along
with diminished CD3
A panel of monoclonal antibodies were used to detect
CD16, MHCII, CD3 surface antigens individually on
splenic DCs for tracking the phenotypic changes of sple-
nocytes after immunization. It has been known that
CD16-mediated signal transduction promotes induction
of maturation of immature DCs and CD16-mediated
antigen uptake potently enhances antigen presentation
[20, 21]. Expression of MHCII surface antigen identifies
antigen presentation, DCs morphology, and expression
of co-stimulatory molecules [22]. While CD3 expression,
T-cell co-receptor is a protein complex, reflects the
ligation of CD3 with T complex receptor (TCR) induced
by MHCII:core recombinant peptide ligation. Because,
multiple immune defects had been described in patients
with chronic HCV infection that may be linked to the
reduced INF-α production, including insufficient re-
sponse of CTL, low activity of natural killer cells (NK
cells), we tested the hypothesis that immunizing mice
with DCs pre-stimulated with BCE may have a better
antigen presenting capacity and NK activity. Using
flow cytometry we found iDCs-core was the only
group that showed a significant phenotypic change
characterized by the difference in surface antigens
expression when compared to RPMI - 1640 group (p <
0.05, n = 6) as follows; 197.9 % increase expression of
CD16 surface antigen; 32 % increase expression of MHCII
surface antigen; while 43 % decrease expression of CD3
surface antigen (Fig. 1).
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High Th1 cytokines versus low Th2 cytokines
A number of studies recently described a significant
down-regulation of DCs function in HCV infected pa-
tients, shifting the Th1 (INF-γ and IL-12) /Th2 (IL-4 and
IL-10) balance towards Th2 up-regulation [7–15, 17–23]
(https://dragonherbarium.com/products/barberry-root-bark-
c-s-wc-berberis-vulgaris).
In order to address the possible modulation in the T
helper 1 (Th1)/T helper2 (Th2) cytokines gene expres-
sion after mice immunization, the difference in mRNA
expression of Th1 cytokines (Interferon-gamma (INF-γ)
and interleukin (IL) -12p40) and Th2 cytokines (IL-4
and IL-10) were evaluated by RT-PCR analysis. Th1 cy-
tokines gene expression exhibited a noticeable up-
regulation (Fig. 2). Levels of INF-γ mRNA increased in
iDCs-core group only. IL-12p40 increased in all groups
immunized with different subsets of DCs with the high-
est IL-12p40 gene expression in iDCs-core group when
compared to negative control group. On the other hand,
mRNA levels of IL-4 exhibited down-regulation in all
groups immunized with different subsets of DCs with
the lowest level reported at in nDCs group. A dramatic
down-regulation in IL-10 was recorded, except for nDCs
group that showed an unexpected increase (Fig. 2).
High protein expression of intrasplenic INF-γ correlates
with elevated levels of mRNA Th1 cytokines and reduced
mRNA levels of Th2 cytokines
mRNA level of INF-γ was verified by evaluating protein
expression of INF-γ using ELISA (Fig. 3). In vivo
immunization of BALB/c mice with different subsets of
DCs, resulted in an increase of protein levels of INF-γ in
iDCs and iDCs-core groups by 22 % and 47.7 %, respect-
ively (p < 0.05, n = 6).
Mice group that received BCE-induced-core-pulsed DCs
had a good T lymphocyte suppression capacity only
when co-cultured with EL4-core cells
A recent study reported that myeloid DCs have an up-
regulated cytotoxic activity to kill T cells during HCV
chronic infection, which represent a novel mechanism of
HCV evasion [22]. EL4 cells (ATCC® TIB39 ™) is a
lymphoma cell line induced in a C57BL mouse by 9,10-
dimethyl-1,2-benzanthracene.
To investigate the anti-core T lymphocyte activity of
immunized mice’s splenocytes, EL4 target cells (T) were
co-cultured with splenocyte effector cells (E) of immu-
nized mice [24]. The optimum co-culture ratio of E:T
cells was 1:1.6 and determined by measuring cytotoxicity
of the co-culture of splenocytes of non-treated mice and
murine EL4 lymphoma cells using MTT cell viability
assay. Cytotoxicity of EL4 cells (transduced and non-
transduced) co-cultured with splenocytes of immunized
mice was represented by the percentages of cell viability
(MTT assay), and cell killing (LDH leakage). Cell viabil-
ity of iDCs-core mice group significantly decreased (p <
0.05) by 12.4 % when co-cultured with EL4-core cells
(Fig. 4)., This was associated with increased cell killing
(57.9 %), in comparison with EL4 + RPMI - 1640 How-
ever, the rest of mice groups had no significant differ-







RPMI nDCs nDCs-Core iDCs iDCs-Core
MHCII CD3 CD16
Fig. 1 Effect of immunization with different subsets of DCs on surface marker expression in splenocytes of immunized mice. Splenocytes of
immunized mice with BCE-induced-core pulsed dendritic cells, in a 3-dose immunization schedule at 4 weeks intervals, shows an elevated CD16+and
MHCII+ populations when compared to RPMI - 1640 group. Spleens of immunized mice were dissociated by gentleMACS dissociator, as described in
Materials and Methods, into a single-cell suspension. Freshly isolated splenocytes were stained with MHCII-FITC, Fcγ RIII/CD16-APC, and CD3-PE monoclonal
antibodies and analyzed by flow cytometry. Data are shown as the percentage of splenocytes bearing surface antigen over total splenocytes population. *
indicates a significant difference with RPMI group. Results are means ± SD of splenocytes of six mice. (PRPMI - 1640 group that received complete medium,
nDCs group that received non-BCE-induced DC, nDCs-core group that received non-BCE-induced DCs transduced with core protein, iDCs
group that received BCE-induced DCs, iDCs-core group that received BCE-induced DCs transduced with core protein)
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Potent and specific anti-core IgG antibodies only in the
group that was immunized with BCE-induced-core-pulsed
DCs
Anti-HCV core IgG antibodies levels in the serum of
each immunized mouse were monitored to assess the
humoral immune response of mice to injection with
DCs. Anti-core IgG antibodies were detected in the sera
of iDCs-core group only when incubated with core re-
combinant protein at a percentage of 21.9697 % after
one week of the last subcutaneous boosting dose (p <
0.05, n = 6). No antibodies were detected when iDCs-
core sera when incubated with NS3 protein. On the
other hand, a minor percentage of antibodies against
core and NS3 proteins was detected in groups of RPMI -
1640 and nDCs, but did not reach the value of a positive
specific anti-core IgG (Fig. 5).
Discussion
Impaired cellular functions of immune system upon HCV
Impairment of the maturation process in dendritic cells
(DCs) is one of the mechanisms responsible for immune
evasion of hepatitis C virus (HCV) [6]. A study reported
that myeloid DCs have an up-regulated cytotoxic activity
to kill T cells during HCV chronic infection, which repre-
sents a novel mechanism of HCV evasion [22]. HCV core
protein can interact with multiple cellular factors, and
regulate expression of cellular genes and control signaling
pathways of different cell types, including DCs [25, 26].
Several studies have shown that core protein may have
a pro-apoptotic activity by affecting the tumor necrosis
factor receptor (TNFR) signaling pathway. Since lym-
photoxin β receptor (LTβR) is involved in apoptotic sig-
naling, this suggests that core protein may have an
immunomodulatory function and may also play a critical
role in the establishment of HCV persistence and in dis-
ease pathogenesis [26, 27]. Therefore, the cytoplasmic
domain of LTβR and TNFR1 signaling is important for
the microenvironment that allows interactions of lym-
phocytes with antigen presenting cells and for B cell mi-
gration and differentiation into antibody-producing cells.
Impairment of these functions may interfere with the
elimination of infected cells and neutralization of virus.
[28] Core protein reduces sensitivity to tumor necrosis
factor (TNF) and activates nuclear factor kappa B
Fig. 2 Effect of mice immunization on the expression of splenic INF-γ, IL-12p40, IL-4 and IL-10 respectively. Cytokine profile of splenocytes of mice
immunized with BCE-induced-core-pulsed DCs exhibits a great shifting towards up-regulating Th1 cytokine profile and down-regulating
Th2 cytokine profile. Specific PCR amplification of reverse-transcribed total RNA (1 μg) from 1 × 106 of splenocytes of mice immunized























Fig. 3 Cytolytic protein expression of INF-γ after mice immunization. Mice immunized with iDCs or iDCs-core cells increases intrasplenic
IFN-γ production in their splenocytes when compared to RPMI group and/or nDCs and nDCs-core groups. Cytoplasmic contents of cytokines protein
expression of INF-γ was assessed from 1 × 106 of splenocytes using ELISA as previously mentioned at material and methods. Data are shown as the
percentage of splenocytes bearing surface antigen over total splenocytes population. * indicates a significant difference with RPMI- 1640 group. Results
are means ± SD of splenocytes of six mice. # indicates a significant difference within nDCs, and nDCs-core groups
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(NFkB), thus inhibiting apoptosis either constitutively or
in response to cytokines [29]. HCV can infect T cells, so
any decrease in the apoptosis thresholds by core may
impair their activation and cytotoxic functions. Since
HCV can infect lymphocytes, increasing their sensitivity
to apoptotic stimuli affects their activation and immune
functions. In chronic infection, few HCV specific cyto-
toxic T lymphocytes (CTL) are found in the peripheral
blood, which could be due to an abnormal death of
activated CTL [30, 31].
Interaction of virus particle with cell surface mole-
cules, such as CD81, may modulate cell signaling. CD81
is widely expressed and found on natural killer (NK)
cells. Inhibition of interferon-gamma (INF-γ) production
by NK cells could alter the development of a T helper 1
(Th1) response and favor a T helper 2 (Th2). Inhibition
of the innate immune response early after infection
could confer a growth advantage to HCV that could not
be controlled by the adaptive immune response. The in-
efficient NK cell response could allow the selection of
escape variants [32]. Compared to monocyte-derived
DCs from healthy donors, DCs from patients with
chronic HCV infection showed an impaired ability to
stimulate allogeneic T cells and to produce interferon
(INF) [33]. This impaired maturation of DCs has been
correlated with persistent HCV infection, [34, 35] and
that’s the main scope of the current study.
Role of BCE on DCs enrichment
A number of studies described a significant down-
regulation of DCs function in HCV infected patients,
shifting the Th1/Th2 balance towards Th2 up-regulation
[7], so a therapeutic DCs vaccine may hold its promises
by ex vivo maturation and stimulation of DCs, because
DCs of chronically infected patients are under a negative
regulation of the virus itself. It was demonstrated that
treatment of macrophages and DCs with berberine; a
benzodioxoloquinolizine alkaloid present in Berberis
vulgaris plant, significantly induced interleukin (IL) -12
production in a dose-dependent manner, leading to the
inhibition of Th2 cytokine profile in CD4+ T cells which
was also observed in our results (Table 1) with a de-


















Splenocytes of immunized mice co-cultured with EL4 cells
MTT (Viability %) LDH (Cell killing %)
Fig. 4 Splenocytes of iDCs-core group have a good T lymphocyte
suppression capacity only on EL4-core cells. Splenocytes of immunized
mice (E) were co-cultured with EL-4 or EL-4-core cells (T) at a ratio of
1:1.6 E:T. EL-4 cells were transduced with core recombinant peptides
using BioPORTER quickEase protein delivery Kit as previously described.
Co-cultured cells were incubated at 37 °C for 4 h and their cytotoxicity
was assessed using MTT viability test and LDH release. Data are shown
as the percentage of splenocytes bearing surface antigen over total
splenocytes population. * indicates a significant difference with RPMI
group. Results are means ± SD of splenocytes of six mice. # indicates a

























Anti-Core response  against
NS3 Protein (Negative
control)
Anti-Core response  against
Core Protein
Fig. 5 Antigen-specific IgG antibodies generated in mice by immunization with DCs. Humoral response assessment revealed potent and specific
anti-core IgG antibodies (total IgG) only in iDCs-core group. Detection of igG antibody responses to the HCV core protein in immunized mice by
ELISA. Pooled sera (1:50 dilution) from each group were incubated in wells coated with recombinant HCV core protein (NS3 protein was used as
a negative control) and detected by a goat anti-mouse secondary antibody (immuno- globulin) conjugated to alkaline phosphatase. The results
are expressed as the optical densities (O.D.) at 405 nm. * indicates a significant difference among groups. Results are means ± SD of sera of six mice
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and mRNA level [13–15, 17–36] (https://dragonherbarium.
com/products/barberry-root-bark-c-s-wc-berberis-vulgaris).
In the present study, results of phenotypic characterization
of immunized mice’s splenocytes proved that barberry
crude extract (BCE) was the most powerful inducer
for splenic cells to express DCs surface markers with
acquiring the functional characteristics associated with
DCs. The maximal increase CD11c+ cells of animal
model (A) after BCE intravenous injection by 10 folds
with an increase in MHC II surface marker which in-
dicate an increase in antigen presenting capacity
(Table 1).
CD11c increase in DCs treated with BCE had
exceeded the conventional DCs stimulators such as re-
combinant granulocyte-macrophage colony-stimulating
factor (GM-CSF) and recombinant fms-like tyrosine
kinase receptor-3 (Flt3) ligand according to a study by
Berhanu el al. [37] These workers found that BALB/c
mice subcutaneous injection with GM-CSF had ex-
panded splenic CD11c+ cells by about one fold, and Flt3
ligand injection expanded them by about five folds,
whereas the combinatory GM-CSF and Flt3 ligand injec-
tion had expanded CD11c+ cells by 9 folds.
CD16-mediated signal transduction promotes induc-
tion of maturation of immature DCs and CD16-
mediated antigen uptake potently enhances antigen pres-
entation [20, 21]. CD16+ cells in iDCs-core splenocytes
exceeding those in RPMI - 1640 group by approximately
3 folds, reflected an up-regulation in pro-inflammatory
cytokines that might represent DCs precursors. More-
over, it might indicate an elevated phagocytic activity
and antigen presenting capacity of the same group [38].
Elevated expression of major histocompatibility (MHC)
II surface antigen on splenocytes of iDCs-core group
identified a high regulation of antigen presentation, DCs
morphology, and expression of co-stimulatory molecules
which was supported by Banchereau, et al. [22] Al-
though CD16 is not DCs specific, it was found on a
limited number of other cell types like NK cells and
macrophages [39]. However, co-expression of CD16 with
MHC-II has been previously described by Haverson [40]
as being characteristic for DCs in the porcine intestinal
lamina propria. While another important marker for
splenic DCs is CD11c, since the injected cells used for
immunization were solely CD11c+. Low CD3+ cells from
immunized mice may be attributed to the architectural
changes in the T cell receptor (TCR):CD3 complexes
induced by MHCII:core protein ligation after
immunization with DCs induced by BCE and pulsed
with core protein (as MHCII T cell interaction complex
causes internalization and degradation of CD3 antigen).
The rate of TCR internalization did not increase signifi-
cantly, while the binding of a peptide: MHCII ligand to
the TCR promoted significant down-regulation of TCR
complexes. This trend suggested that the binding of the
ligand blocks TCR complexes from returning to the cell
surface rather than increasing the rate of internalization
of TCR complexes expressed on the cell surface [41].
The present phenotypic reports clearly emphasized the
important role BCE on DCs enrichment and maturation.
It also emphasized that immunization with BCE-induced
DCs might counteract DCs defects that took place upon
HCV infection.
Vaccine-mediated immune response
HCV core protein triggered monocyte-derived IL-10
productions. This cytokine, in turn, has led to DCs
apoptosis and impaired production of interferon-alpha
(INF-α), thus closely resembling the DCs defects seen in
chronically HCV-infected patient. Multiple immune
defects have been described in patients with chronic
HCV infection that might be linked to the reduced INF-
α production, including insufficient response of CTL,
low activity of NK cells, and production of antibody with
low neutralizing capacity [42, 43]. Most antigens and
vaccines trigger both B and T cell responses, such that
there is no rationale in opposing antibody production
(humoral immunity) and T cell responses (cellular
immunity). In addition, Th cells are required for most
antibody responses, while antibodies exert significant
influence on T cell responses to intracellular pathogen
[44, 45]. Vaccine–induced immune effectors are essen-
tially antibodies produced by B lymphocytes and capable
of binding specifically to a toxin or a pathogen peptide.
Other potential effectors are CTL that may limit the
spread of infectious agents by recognizing and killing
infected cells or secreting specific antiviral cytokines.
The generation and maintenance of both B and CTL
responses is supported by growth factors and signals
provided by Th cells. These effectors are controlled
by regulatory T cells that are involved in maintaining
immune tolerance.
Table 1 Phenotyping analysis of DCs
Parameters BCE-induced-DCs Non-BCE-induced-DCs
CD11c (%) 16 ± 0.9 1.5 ± 0.01
MHCII (%) 13 ± 0.4 8 ± 0.3
IL4 (fold) 0.31 ± 0.01 0.61 ± 0.002
IL 10 (fold) 0.27 ± 0.03 0.73 ± 0.002
IL 12 (fold) 0.74 ± 0.005 0.2 ± 0.003
INF (fold) 1.3 ± 0.05 0.56 ± 0.002
IL 12 (Pg/ml) 4.5 ± 0.3 1.2 ± 0.1
INF-gamma (Pg/ml) 35 ± 3.2 22.5 ± 1.2
The level of CD11c and MHCII were detected by FACSCalibur flow cytometer
(BD Biosciences). cytokines expression (IL4, IL10, IL 12 and INF-gamma) was
performed by RT-PCR. IL 12 and INF-gamma proteins levels were measured by
ELISA (Komabiotech, Korea)
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Anti-core cellular response
The communication between DCs and T cells in this
area of host–pathogen interaction seems to be a dia-
logue rather than a monologue in which mature DCs re-
spond to T cells as well. In the process of studying DCs
vaccine, it is worth mentioning that INF-γ, IL-12, IL-4,
IL-10, and other cytokines had a crucial role in manipu-
lating a potent anti-HCV cellular immune response after
vaccination. Up-regulation of Th1 cytokines (e.g. IL-12,
INF-γ) and down-regulation of Th2 cytokines (e.g. IL-4,
IL-10) and nitric oxide (NO) were the major targets to
retain the th1/th2 balance corrupted by HCV viral infec-
tion and have an adequate anti-HCV cellular immune
response. Interferons are key players of the innate im-
mune response to virus infection. The production of
INF-γ (type II INF) is restricted to cells of the immune
system, such as NK cells, macrophages, and T cells [46].
IL-12, which is known to be the primary stimulator of
NK cells and INF-γ, induce Th1 type cytokines and fos-
ter CTL development. IL-12 is, therefore, critical in a
series of immune-pathological conditions, such as viral
infections and tumors [47, 48]. On the other hand, IL-4
exists in elevated levels in sera of HCV infected patients
than non-infected ones [49]. It is known to down-regulate
cell-mediated immune effector mechanisms important in
the host defense against intracellular pathogens [50]. IL-
10 is a pleiotropic cytokine traditionally considered as
immunosuppressive and anti-inflammatory, produced by
many cell types, [51, 52] which exerts its effects by inhibit-
ing macrophage and DCs functions. In chronic HCV
infection, patients have high serum levels of IL-10, associ-
ated with incomplete responses to INF therapy [53].
RT-PCR analysis of immunized mice splenocytes m-
RNA demonstrated an increase in mRNA expression of
IL-12p40 and INF-γ transcripts in iDCs-core, and iDCs
groups (Fig. 2), indicating a potent up-regulation in Th1
arm. While a down-regulation in mRNA expression in
IL-10 transcripts was demonstrated at all groups that
were immunized with different subsets of DCs with the
lowest IL-10 mRNA expression in case of iDCs-core
group (Fig. 2), indicating a down-regulation in Th2 arm.
Protein expression of intrasplenic INF-γ, (the target
protein) was high and in accordance with its mRNA
expression (Fig. 3). This ascertains that the immune
system is having a better struggle with the viral infec-
tion to prevent its persistency. On the other hand,
protein expression of IL-12 was unexpectedly dimin-
ished. One mechanism that might account for the
low intra-splenic IL-12 protein level was that it might
be consumed by the cells [54]. Alternatively, IL-12
has a half-life of only 12 h), [55] or may have re-
leased out of the cell and functioned extracellularly.
This postulate was assisted by the up-regulation of
splenic IL-12p40 mRNA expression.
In the present study, the strongly reduced extracellular
levels of blood NO of all immunized mice with different
DCs subsets, with the lowest NO level in iDCs-core
group, was indicative for a selective and persistent up-
regulation of T cells INF-γ production. This finding was
supported by Roozendaal et al. [56] where NO was able
to modulate the balance between the expression of Th1-
and Th2-type cytokines through selective and persistent
inhibition of expression of INF, shifting Th1/Th2 balance
towards Th2 cytokines. It is worth noting that the main
function of this vaccine was to counteract the effect of
HCV infection of misbalancing the Th1/Th2 model.
CTL assay was performed to determine and quantitate
the capacity of effector pre-induced cells (splenocytes of
nDCs-core, iDCs-core groups individually), to eliminate
target cells (EL4-core cells). The principle of this assay
was to prime T cells to be antigen-specific through the
immunization process and then, upon repeated exposure
to a specific antigen, induce a rapid T cell expansion.
The study carried out to determine the best number of
co-culture between splenocytes and EL4 proved to be es-
sential to ensure that EL4 and splenocytes were able to
be cultivated together, and to determine the optimum
effector:target cells ratio with the highest viability to use
it for T lymphocyte suppression assay. CTL assay
showed that splenocytes of iDCs-core group had a good
T lymphocyte suppression capacity only on EL4-core
cells (Fig. 4), indicating a specific T response to the
core-pulsed cells. In this experiment, DCs have been
successfully used as cellular adjuvants in mice to elicit
protective T cell immunity against HCV core protein.
Anti-core humoral response
To determine if adequate levels of antibodies had been
attained following vaccination, IgG antibodies recogniz-
ing HCV core protein were measured. Humoral response
assessment revealed specific anti-core IgG antibodies
only in iDCs-core group, with a remarkable high per-
centage against negative control (Fig. 5). This result re-
flects a significant B cells activation to produce specific
antibodies against core protein. Interestingly, iDCs-core
group that demonstrated the most significant humoral
response also showed the highest cellular immune
response.
In conclusion, the present study provides evidence for
the role of BCE on stimulating splenic DCs proliferation,
on both sides of DCs maturation and count. In addition,
the basics for a novel vaccination strategy to treat HCV
were manipulated, through analyzing the humoral and
cellular immune response upon immunizing mice with
different subsets of treated DCs. Therapeutic efficacy of
BCE synergized core-pulsed DCs vaccination exhibited an
interesting anti-core boosting effect against a tumor model
expressing HCV core protein in an immunocompetent
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host (EL4-core cells). DCs are essential for T cells activa-
tion and since viral clearance in HCV infected patients is
associated with a vigorous T cells response, a new type of
HCV vaccine of a strong antigenicity in humoral and cellu-
lar immunities was proposed, based on ex-vivo stimulated
HCV core protein-pulsed DCs and promoted by BCE
treatment. This vaccine might have a therapeutic setting to
potentially circumvent the diminished and down-regulated
DCs function of HCV infected patients by giving the
necessary maturation stimuli whether in vivo (BCE treat-
ment) or in ex vivo (core protein transduction). As a thera-
peutic immunization approach, this vaccine may pertain
new aspects compared to other vaccines, which are faced
in HCV infected patients with down-regulated DCs
function.
It is crucial that further studies should be carried out
to reliably move this preclinical study to a clinical one.
The ultimate goal in the near future is to conduct some
research on the CD4 and CD8 T responses, and IL-28b
monitoring, in order to full scheme the therapeutic in-
fluence of the proposed vaccine. Working on peripheral
blood of HCV infected patients should be included. Fi-
nally, further clinical studies should be carried out on
pegylated interferon non-responders HCV patients with
low doses of vaccine tailored from each patient’s blood,
for tracking its therapeutic effect.
Conclusion
Because DCs are essential for T cell activation and since
viral clearance in HCV infected patients is associated
with a vigorous T cell response, this study proposed a
new type of therapeutic HCV vaccine model of a strong
antigenicity in humoral and cellular immunities, based
on ex vivo stimulated HCV core protein-pulsed DCs and
promoted by BCE treatment. This model might be used
in a therapeutic setting to circumvent the diminished
and down-regulated DCs function of HCV infected
patients. As a therapeutic immunization approach this
vaccine may present important new aspects since other
vaccines are faced in HCV infected patients with the
described down-regulated DCs function.
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